Evidence map›Paper›PMID 36697496›Full record

ArticleCommunications biology2023

Comparing the SARS-CoV-2-specific antibody response in human milk after homologous and heterologous booster vaccinations.

Sien J Mulleners, Hannah G Juncker, Eliza J M Ruhé, Aniko Korosi, Johannes B van Goudoever, Marit J van Gils, Britt J van Keulen

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sien J Mulleners *Emma Children's Hospital, Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Center (location VUmc), De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
Hannah G Juncker *Emma Children's Hospital, Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Center (location VUmc), De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
Eliza J M RuhéEmma Children's Hospital, Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Center (location VUmc), De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
Aniko KorosiSwammerdam Institute for Life Sciences, Science Park 904, 1098 XH, Amsterdam, The Netherlands.
Johannes B van GoudoeverEmma Children's Hospital, Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Center (location VUmc), De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands. h.vangoudoever@amsterdamumc.nl.ORCID 0000-0003-3960-1703
Marit J van GilsAmsterdam Infection and Immunity Institute, Amsterdam University Medical Center (location AMC), Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.ORCID 0000-0003-3422-8161
Britt J van KeulenEmma Children's Hospital, Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Center (location VUmc), De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
Emma Kinderziekenhuis · NLNetherlands Institute for Neuroscience · NLAmsterdam University Medical Centers · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human milk contains SARS-CoV-2-specific antibodies after COVID-19 vaccination. These milk antibodies decrease several months post-vaccination. Whether booster immunization restores human milk antibody levels, potentially offering prolonged passive immunity for the infant, remains unknown. In this prospective follow-up study, we investigated the longitudinal SARS-CoV-2-specific antibody response in human milk of 26 lactating women who received a COVID-19 booster dose of an mRNA-based vaccine. Moreover, we evaluated whether the booster-induced human milk antibody response differs for participants who received a similar or different vaccine type in their primary vaccination series. All participants (100%) who received a homologous booster vaccination showed SARS-CoV-2-specific immunoglobulin A (IgA) and immunoglobulin G (IgG) in their milk. Heterologous booster vaccination resulted in milk conversion for 9 (69%) and 13 (100%) participants for IgA and IgG respectively. Findings of this study indicate that both homologous and heterologous boosting schedules have the potential to enhance SARS-CoV-2-specific IgA and IgG in human milk.

Indexed as

COVID-19Milk, HumanAntibodies, ViralAntibody FormationCOVID-19 VaccinesFemaleFollow-Up StudiesHumansImmunoglobulin AImmunoglobulin GInfantLactationProspective StudiesSARS-CoV-2Antibodies, ViralCOVID-19 VaccinesImmunoglobulin AImmunoglobulin G

Identifiers

PMID36697496
PMCPMC9875178
OpenAlexW4318044494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.